University of Connecticut University of UC Title Fallback Connecticut


Pre-K Scholar Career Development Award Program

CICATS Pre-K Career Development Award Program is now accepting applications. This program is designed to equip junior faculty with the knowledge and competencies to effectively apply for a NIH Research Career Development Award (K award) as well as to become leaders in clinical and translational science. If you are interested learning more or submitting an application click here.

Deadline: January 31, 2018


Funding Opportunity

Funded by The Kavli Foundation, CICATS Science Cafés create a social environment for individuals to interact and discuss innovative ideas about translational science and scientific research in general. This Science Cafe funding opportunity is open to UConn Health and UConn Storrs. Read more.

Deadline: Ongoing

health equity

Visualize Health Equity

Two UConn M.D. candidates were selected for inclusion in the National Academy of Medicine's permanent online art gallery about health equity. Both pieces are currently featured on our blog. Read more.


Dr. Cato T. Laurencin Receives New Appointment

CICATS Chief Executive Officer Dr. Cato Laurencin has been appointed by the U.S. Secretary of Commerce to the National Medal of Technology and Innovation Nomination Evaluation Committee. Read more.

sci cafe

Science Café on Structural Biology Meets Drug Discovery Finds Great Success

The UConn Partnership for Excellence in Structural Biology, a CICATS Core Interest Group, held a Science Café on Structural Biology Meets Drug Discovery on September 11, 2017 at the Nathan Hale Inn on the UConn Storrs campus. Read more.


CIG Directors Lead World’s First Ovarian Cancer Vaccine Trial

Three directors from two of CICATS’ Core Interest Groups: Women’s Cancer Consortium Core Interest Group (CIG) and the Personalized Immunotherapy CIG: Dr. Pramod Srivastava, Dr. Susan Tannenbaum, and Dr. Molly Brewer, are part of the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. Read more.